Skip to content
FAP News Today logo
  • About FAP
    What is FAP?
    Symptoms
    Diagnosis
    Causes
    Life expectancy and prognosis
  • Treatments
    Approved treatments
    Experimental treatments
  • News
  • Columns
    Rumination and Response — Ezekiel Lim
    Sunrise Sunset — Jaime Christmas
  • Health insights
  • FAQs
  • What can we help you find today?

February 5, 2020 News by Larry Luxner

With Post-Brexit Move to Amsterdam Complete, EMA Renews Rare Disease Focus

The gleaming new Dutch headquarters of the European Medicines Agency (EMA), fronting Domenico Scarlattilaan in Amsterdam’s suburban Zuidas business district, finally opened for business last month — just over two years after the European Union decided to relocate the EMA to the Netherlands in the wake of Brexit.

Recent Posts

  • Sudoscan skin test may monitor FAP progression: Study
  • Family members of late-onset FAP patients face unique challenges
  • An experimental gene therapy gives me hope for my children
  • Tafamidis meglumine safely slows FAP progression: Brazil study
  • 1st FAP patient dosed in Phase 3 trial of gene therapy nex-z


Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: info@bionews.com
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.